Type of insulin regimen | Total (N = 3) | Premixed (N = 1) | Long-acting (N = 1) | Premixed + rapid- or short-acting (N = 1) | Long-acting + rapid- or short-acting (N = 0) |
---|---|---|---|---|---|
Placebo | |||||
 Before first dose reduction | |||||
  Cumulative exposure (subject-year) | 0.72 | 0.23 | 0.26 | 0.23 | – |
  Number of events | 16 | 14 | 0 | 2 | – |
  Incidence per subject-year exposure | 22.31 | 60.88 | 0 | 8.70 | – |
 After first dose reduction | |||||
  Cumulative exposure (subject-year) | 0.18 | 0.08 | 0.03 | 0.08 | – |
  Number of events | 5 | 4 | 0 | 1 | – |
  Incidence per subject-year exposure | 27.26 | 52.18 | 0 | 13.04 | – |
Type of insulin regimen | Total (N = 14) | Premixed (N = 4) | Long-acting (N = 5) | Premixed + rapid- or short-acting (N = 0) | Long-acting + rapid- or short-acting (N = 5) |
---|---|---|---|---|---|
Canagliflozin 100Â mg | |||||
 Before first dose reduction | |||||
  Cumulative exposure (subject-year) | 1.54 | 0.42 | 0.59 | – | 0.53 |
  Number of events | 72 | 22 | 20 | – | 30 |
  Incidence per subject-year exposure | 46.88 | 52.87 | 33.98 | – | 56.48 |
 After first dose reduction | |||||
  Cumulative exposure (subject-year) | 2.55 | 0.64 | 0.93 | – | 0.98 |
  Number of events | 62 | 17 | 18 | – | 27 |
  Incidence per subject-year exposure | 24.27 | 26.65 | 19.28 | – | 27.47 |